Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 20/20 | 0.62 |
| ▸ | CHRNA3 | P32297 | 20/20 | 0.62 |
| ▸ | CHRNA4 | P43681 | 20/20 | 0.62 |
| ▸ | CHRNB3 | Q05901 | 20/20 | 0.62 |
| ▸ | CHRNA6 | Q15825 | 20/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19948600 | 0.87 | CHRNB2 (0.61) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL1404444 | 0.87 | CHRNB2 (0.61) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| Hydrochloric Acid SCHEMBL5965871 | 0.85 | CHRNB2 (0.59) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL30259993 | 0.83 | CHRNB2 (0.45) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL30259987 | 0.83 | CHRNB2 (0.53) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL30260009 | 0.83 | CHRNB2 (0.53) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL1588528 | 0.83 | CHRNB2 (0.53) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| Hydrochloric Acid SCHEMBL7006653 | 0.83 | CHRNB2 (0.57) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL23003576 | 0.81 | CHRNB2 (0.43) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL14919447 | 0.81 | CHRNB2 (0.43) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746963-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | claimed |
| WO-2025017045-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2025-01-23 | — | — | WO | claimed |
| EP-4746963-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| EP-4739670-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-13 | — | — | EP | disclosed |
| US-20250368649-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2025-12-04 | — | — | US | disclosed |
| WO-2025235833-A1 | RXFP1 RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2025-11-13 | — | — | WO | disclosed |
| US-20250289830-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2025-09-18 | — | — | US | disclosed |
| US-12351591-B2 | KRas inhibitors | ELI LILLY AND COMPANY (US) | 2025-07-08 | — | — | US | disclosed |
| EP-4540254-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| WO-2025064853-A1 | RIPK3 INHIBITORS AND METHODS OF USE | Momentum Therapeutics, Inc. (US) | 2025-03-27 | — | — | WO | disclosed |
| WO-2025017045-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2025-01-23 | — | — | WO | disclosed |
| WO-2023244604-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023168298-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023148129-A1 | IMIDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-10 | — | — | WO | disclosed |
| US-20230023851-A1 | HER2 MUTATION INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2023-01-26 | — | — | US | disclosed |
| CN-115151257-A | Novel compounds for the treatment of diseases associated with DUX expression | FACIO知识产权有限公司 | 2022-10-04 | — | — | CN | disclosed |
| WO-2022003575-A1 | HER2 MUTATION INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2022-01-06 | — | — | WO | disclosed |
| US-10913753-B2 | Thienopyridine carboxamides as ubiquitin-specific protease inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| EP-3371151-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | Agency For Science, Technology And Research (SG) | 2018-09-12 | — | — | EP | disclosed |
| WO-2017061957-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913753-B2 | Thienopyridine carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | CHRNB2 3612/4885CHRNA3 3245/4885CHRNA4 3594/4885 |
| US-20250368649-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | CHRNB2 4879/4885CHRNA3 4865/4885CHRNA4 4869/4885 |
| US-12351591-B2 | KRas inhibitors | KRAS, NRAS, HRAS | CHRNB2 4853/4885CHRNA3 4833/4885CHRNA4 4868/4885 |
| US-20250289830-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | CHRNB2 4853/4885CHRNA3 4833/4885CHRNA4 4868/4885 |
| US-20230023851-A1 | HER2 MUTATION INHIBITORS | ERBB2, EGFR, ERBB3 | CHRNB2 4150/4885CHRNA3 4324/4885CHRNA4 4617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.